Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rapport Therapeutics (RAPP) Research & Development (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Research & Development data on record, last reported at $32.7 million in Q1 2026.

  • On a quarterly basis, Research & Development rose 67.16% to $32.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $107.9 million, a 58.72% increase, with the full-year FY2025 number at $94.8 million, up 55.56% from a year prior.
  • Research & Development reached $32.7 million in Q1 2026 per RAPP's latest filing, up from $30.3 million in the prior quarter.
  • Over the last five years, Research & Development for RAPP hit a ceiling of $32.7 million in Q1 2026 and a floor of $4.7 million in Q2 2023.
  • A 4-year average of $17.7 million and a median of $16.4 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 232.32% in 2024, then soared 43.34% in 2025.
  • Tracing RAPP's Research & Development over 4 years: stood at $11.8 million in 2023, then skyrocketed by 45.77% to $17.2 million in 2024, then surged by 75.93% to $30.3 million in 2025, then grew by 8.12% to $32.7 million in 2026.
  • Business Quant data shows Research & Development for RAPP at $32.7 million in Q1 2026, $30.3 million in Q4 2025, and $22.3 million in Q3 2025.